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The introduction of antimicrobial drugs in clinical practice
is usually followed by the emergence of resistant strains.
The inadequate use, auto-medication, exclusive use of
extended-spectrum drugs, or the premature break of anti-
microbial treatments are factors to take in consideration.1
Multiresistant extended-spectrum b-lactamase (ESBL)
producing-Escherichia coli are among the top six most
worrying human pathogens.2 This organism is a common
inhabitant of the human intestinal tract but, in certain
cases, it may cause infectious diseases, such as enteric,
lung, nervous, and urinary tract infections. In recent years,
E. coli strains have been developing resistance to some
antimicrobial agents used to treat infections and are
associated with therapeutic failure, causing great
concern.3
Sixty-five ESBL-producing E. coli isolates, obtained from
individual human urine samples,were selected for study. The
isolates were obtained monthly from urine samples of
patients at the Hospital Center of Tra´s-os-Montes and Alto
Douro, fromNovember2009 to January 2011. Susceptibility to
16 antibiotics (ampicillin, amoxicillin þ clavulanic acid,
cefoxitin, cefotaxime, ceftazidime, aztreonam, imipenem,
gentamicin, amikacin, tobramycin, streptomycin, nalidixic
acid, ciprofloxacin, sulfamethoxazole/trimethoprim, tetra-
cyclineandchloramphenicol)was testedby thedisk-diffusion
method in all recovered isolates and ESBL-phenotypic
detection was confirmed out by double-disk test according
to the CLSI criteria.4
The presence of resistance genes as well the classifica-
tion in phylogenetic groups (A, B1, B2, or D) were per-
formed by PCR (Table 1).1684-1182/$36 Copyright ª 2012, Taiwan Society of Microbiology. Publ
doi:10.1016/j.jmii.2012.04.003The highest levels of resistance were observed for cefo-
taxime, ciprofloxacin, and nalidixic acid. Other studies in
urinary human E. coli isolates showed lower values.5 We
demonstrated that the CTX-M group of b-lactamases was the
predominant ESBL type identified in our isolates, with the
blaCTX-M-15 being the most frequent bla gene detected. In
Portugal, only dispersed cases of detection of blaCTX-M-15 have
been reported.6 The blaTEM gene was detected in 73.8% of
the isolates, blaSHV in 1.5%, blaOXA in 16.9% and blaCTX-M in
89.2%of the65E coli isolates.Theaac(3)-II genewasdetected
in 97.4% of the gentamycin-resistant isolates; 51.3% of the
streptomycin-resistant isolates presented the aadA gene; the
tet(A) and/or tet(B) geneswere presented in 45.3% and 37.5%
of the tetracyclin-resistant isolates, respectively; the cmlA
gene was detected in 54.5% of the chloranphenicol-resistant
isolates; and sul1, sul2, and/or sul3 were detected in 40%,
37.5%, and 37.5% of the sulfamethoxazol/trimethoprim-
resistant isolates, respectively.
It is important to note that the majority of isolates
belonged to B2 (63.1%) and D (26.1%) phylogroups and
almost all were multi-resistant. The expression of CTX-M-
type b-lactamases may explain this fact.6
The class 1 integron was present in 35.3% of the
sulfamethoxazol/trimetoprim-resistant isolates. The vari-
able region of the class 1 integron was detected in 12
isolates, containing the dfrA15 and aadA1 genes (seven
isolates) or the dfrA17, dfrA2þ and aadA5 genes (five
isolates). These genes were previously detected in E. coli
isolated from human urine samples, conferring resistance
to sulfamethoxazol/trimethoprim and streptomycin,
respectively.7
The gyrA gene presented two mutations causing amino
acid changes (S83L and D87N). These mutations haveished by Elsevier Taiwan LLC. All rights reserved.
Table 1 Phenotypic and genotypic profile of the 59 extended-spectrum b-lactamase producing Escherichia coli isolates rec vered from human urine samples
Isolates Phenotype of
resistance to beta-
lactam antibiotics
Phenotype of resistance
to other antibiotics
Beta-lactamase
genes detected
Other resistant
genes
Amino acid ch nges Genetic elements Phylogenetic
groupsgyrA pa
RP1 AMC-ATM-CTX AMP-TET-GEN-CIP-TOB-NAL blaTEM-1B;
blaCTX-M-15
aac(3)-II; tet(A);
gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477 B2
RP2 AMC-ATM-
CTX-CAZ
AMP-TET-GEN-CIP-TOB-SXT-NAL blaTEM-1B;
blaCTX-M-15
aac(3)-II; aadA;
tet(A); gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477; Int1;
rvint1[dfrA15þaadA1]
B2
RP 3 ATM-CTX AMP-CIP-NAL blaTEM-1B;
blaCTX-M-15
gyrA; parC S83LþD87 N S8 þE84 V ISEcp1; orf477 B2
RP 4 AMC-CTX AMP-TET-GEN-CIP-TOB-
CHL-SXT-NAL-S
blaTEM-1B;
blaCTX-M-15
tet(B); gyrA; parC S83LþD87 N S8 þE84 V ISEcp1; orf477; Int1;
rvint1[dfrA15þaadA1]
B2
RP 5 AM-ATM-
CTX-CAZ
AMP-TET-CIP-TOB-SXT-NAL-STR blaTEM-1B;
blaOXA;
blaCTX-M-15
aadA; tet(A);
gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477; Int1;
rvint1[dfrA15þaadA1]
B2
RP 6 AMC-ATM-
CTX-CAZ
AMP-TET-CIP-TOB-SXT-NAL-STR blaCTX-M-15 aadA; tet(A);
gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; Int1;
rvint1[dfrA15þaadA1]
B2
RP 7 ATM-CTX AMP-TET-GEN-CIP-TOB-NAL blaTEM-1B;
blaOXA;
blaCTX-M-15
aac(3)-II; tet(A);
gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477 B2
RP 8 CTX AMP-GEN-CIP-TOB-NAL blaTEM-1B;
blaCTX-M-15
aac(3)-II; gyrA; parC S83LþD87 N S8 þE84 V ISEcp1 B2
RP 9 ATM-CTX AMP-TET-GEN-CIP-TOB-SXT-NAL blaTEM-1B;
blaCTX-M-15
aac(3)-II; aadA;
tet(A); gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477;
Int1[dfrA1þaadA1]
B1
RP 10 AMC-ATM-CTX AMP-TET-GEN-CIP-
TOB-SXT-NAL-STR
blaTEM-1B;
blaOXA;
blaCTX-M-15
aac(3)-II; aadA;
tet(A); gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477; Int1;
rvint1[dfrA15þaadA1]
B2
RP 11 AMC-ATM-
CTX-CAZ
AMP-TET-CIP-TOB-SXT-NAL blaTEM-1B;
blaCTX-M-15
aadA; tet(A);
gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477; Int1;
rvint1[dfrA15þaadA1]
B2
RP 12 AMC-ATM-
CTX-CAZ
AMP-TET-GEN-CIP-TOB-NAL-STR blaTEM-1B;
blaCTX-M-15
aadA; tet(A);
gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477 B2
RP 13 AMC-ATM-
CTX-CAZ
AMP-TET-GEN-CIP-TOB-NAL-STR blaTEM-1B;
blaCTX-M-15
aac(3)-II; aadA;
tet(A); gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477 B2
RP 14 ATM-CTX-CAZ AMP-TET-GEN-CIP-TOB-NAL blaTEM-1B;
blaCTX-M-15
aac(3)-II; tet(A);
gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477 B2
RP 15 AMC-ATM-
CTX-CAZ
AMP-TET-GEN-CIP-TOB-NAL blaTEM-1B;
blaOXA;
blaCTX-M-15
aac(3)-II; tet(A);
gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477 B2
RP 16 CTX AMP blaTEM-1B;
blaCTX-M-9
ISEcp1; orf477 B2
RP 17 CTX FOX-AMP-TET-GEN-CIP-NAL blaTEM-1B;
blaCTX-M-9
aac(3)-II; tet(B); gyrA;
parC; gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477 B1
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RP 18 CTX-CAZ AMP-TET-GEN-CIP-
TOB-SXT-NAL-STR
blaTEM-1B;
blaCTX-M-9
aac(3)-II; tet(A);
gyrA; parC
S83LþD87 N 0IþE84 V B2
RP 19 ATM-CTX AMP-GEN-CIP-TOB-NAL blaTEM-1B;
blaCTX-M-15
aac(3)-II; gyrA; parC S83LþD87 N 0IþE84 V ISEcp1; orf477 B2
RP 20 AMC-ATM-CTX AMP-TET-GEN-CIP-TOB-
CHL-SXT-NAL-STR
blaTEM-1B;
blaOXA;
blaCTX-M-15
aadA; tet(B);
sul1; sul2;
sul3; gyrA; parC
S83LþD87 N 0IþE84 V B2
RP 21 AMC-ATM-
CTX-CAZ
AMP-TET-GEN-CIP-AK-
TOB-NAL-STR
blaTEM-1B;
blaOXA;
blaCTX-M-15
tet(A); tet(B);
gyrA; parC
S83LþD87 N 0IþE84 V B2
RP 22 AMC-ATM-
CTX-CAZ
AMT-TET-GEN-CIP-AK-
TOB-SXT-NAL-STR
blaTEM-1B;
blaOXA;
blaCTX-M-15
aadA; tet(A); sul1;
sul3; gyrA; parC
S83LþD87 N 0IþE84 V B2
RP 23 AMC-ATM-
CTX-CAZ
AMP-TET-GEN-CIP-TOB-NAL blaTEM-1B;
blaOXA;
blaCTX-M-15
tet(A); gyrA; parC S83LþD87 N 0IþE84 V B2
RP 24 AMC-ATM-
CTX-CAZ
AMP-TET-GEN-CIP-TOB-NAL blaTEM-1B;
blaOXA;
blaCTX-M-15
aadA; tet(A);
gyrA; parC
S83LþD87 N 0IþE84 V B2
RP 25 AMC-ATM-
CTX-CAZ
CAZ-AMP-TET-CIP-TOB-NAL blaTEM-1B;
blaOXA;
blaCTX-M-15
tet(A); gyrA; parC S83LþD87 N 0IþE84 V B2
RP 26 AMC-CTX AMP-TET-GEN-CIP-
TOB-CHL-SXT-NAL-STR
blaTEM-1B;
blaOXA;
blaCTX-M-15
aadA; tet(B); sul1;
sul2; sul3; gyrA; parC
S83LþD87 N 0IþE84 V B2
RP 27 AMC-ATM-
CTX-CAZ
CAZ-AMP-TET-CIP-AK-
SXT-NAL-STR
blaTEM-1B;
blaCTX-M-15
aadA; tet(A);
sul3; gyrA; parC
S83LþD87 N 0IþE84 V B2
RP 28 ATM-CTX AMP-CIP-AK-TOB-NAL blaCTX-M-15 aadA; gyrA; parC S83LþD87 N 0IþE84 V B2
RP 29 AMC-ATM-
CTX-CAZ
AMP-TET-CIP-AK-TB-
CHL-SXT-NAL-STR
blaTEM-1B;
blaCTX-M-15
aadA; tet(B); sul1;
sul3; gyrA; parC
S83LþD87 N 0IþE84 V B2
RP 30 ATM-CTX-CAZ AMP-TET-GEN-CIP-A-
TOB-SXT-NAL-STR
blaTEM-1B;
blaOXA;
blaCTX-M-15
aadA; tet(A); sul1;
sul3; gyrA; parC
S83LþD87 N 0IþE84 V B2
RP 31 AMC-ATM-CTX AMP-TET-GEN-CIP-IMP-
SXT-NAL-STR
blaTEM-1B;
blaCTX-M-9
tet(A); sul1; sul2;
sul3; gyrA; parC
S83LþD87 N 0IþE84 V D
RP 32 ATM-CTX AMP-TET-CIP-SXT-NAL-STR blaTEM-1B;
blaCTX-M-15
sul1; sul2; gyrA; parC S83LþD87 N 0IþE84 V B1
RP 33 ATM-CTX AMP-TET-GEN-CIP-
TOB-C-SXT-NAL-STR
blaTEM-1B;
blaCTX-M-15
aadA; tet(B); sul1; sul2;
sul3; gyrA; parC
S83LþD87 N 0IþE84 V B2
RP 34 ATM-CTX-CAZ AMP-TET-CIP-NAL blaCTX-M-15 gyrA; parC S83LþD87 N 0IþE84 V orf477 D
RP 35 AMC-ATM-CTX AMP-TET-CIP-TOB-C-
SXT-NAL-STR
blaTEM-1B;
blaSHV-12
gyrA; parC S83LþD87 N 0IþE84 V orf477 D
(continued on next page)
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Table 1 (continued )
Isolates Phenotype of
resistance to beta-
lactam antibiotics
Phenotype of resistance
to other antibiotics
Beta-lactamase
genes detected
Other resistant
genes
Amino acid ch nges Genetic elements Phylogenetic
groupsgyrA pa
RP 36 AMC-ATM-CTX AMP-GEN-CIP-TOB-
SXT-NAL-STR
blaTEM-1B;
blaCTX-M-15
aac(3)-II; sul2;
gyrA; parC
S83LþD87 N S8 þE84 V orf477 D
RP 37 AMC-ATM-
CTX-CAZ
FOX-AMP-TET-GEN-
CIP-NAL-STR
blaTEM-1B;
blaCTX-M-15
aac(3)-II; gyrA; parC S83LþD87 N S8 þE84 V orf477 D
RP 38 ATM-CTX-CAZ AMP-TET-GEN-CIP-TOB-
CHL-SXT-NAL-STR
blaTEM-1B;
blaCTX-M-15
cmlA; sul2;
gyrA; parC
S83LþD87 N S8 þE84 V orf477 D
RP 39 AMC-ATM-CTX AMP-TET-CIP-TOB-
CHL-SXT-NAL-STR
blaTEM-1B;
blaCTX-M-15
tet(A); tet(B);
cmlA; gyrA; parC
S83LþD87 N S8 þE84 V orf477 D
RP 40 AMC-ATM-
CTX-CAZ
AMP-TET-GEN-CIP-TOB-NAL blaTEM-1B;
blaCTX-M-15
aac(3)-II; gyrA; parC S83LþD87 N S8 þE84 V D
RP 41 AMC-ATM-
CTX-CAZ
FOX-AMP-TET-GEN-CIP-AK-
TOB-CHL-SXT-NAL-STR
blaTEM-1B;
blaCTX-M-15
tet(B); cmlA;
gyrA; parC
S83LþD87 N S8 þE84 V orf477 D
RP 42 ACM-ATM-CTX AMP-TET-CIP-TOB-
CHL-SXT-NAL
blaTEM-1B;
blaCTX-M-15
aac(3)-II; tet(B); cmlA;
sul2; gyrA; parC
S83LþD87 N S8 þE84 V ofr477 D
RP 43 AMC-CTX AMP-TET-GEN-CIP-
TOB-CHL-SXT-NAL-S
blaTEM-1B;
blaCTX-M-15
aac(3)-II; tet(B); cmlA;
sul2; gyrA; parC
S83LþD87 N S8 þE84 V orf477; Int1;
rvint1[dfrA17þ
dfrA29þaadA5]
D
RP 44 AMC-ATM-CTX AMP-TET-CIP-TOB-CHL-NAL blaTEM-1B;
blaCTX-M-15
tet(A); tet(B);
cmlA; gyrA; parC
S83LþD87 N S8 þE84 V orf477 D
RP 45 AMC-ATM-CTX AMP-TET-GEN-CIP-SXT-NAL blaTEM-1B;
blaCTX-M-15
sul1; sul2; gyrA; parC S83LþD87 N S8 þE84 V orf477; Int1;
rvint1[dfrA17
þdfrA29þaadA5]
B1
RP 46 AMC-ATM-CTX TET-GEN-CIP-IMP-TOB-
CHL-SXT-NAL-STR
blaTEM-1B;
blaCTX-M-15
aac(3)-II; tet(B); cmlA;
sul2; gyrA; parC
S83LþD87 N S8 þE84 V orf477 D
RP 47 AMC-CTX AMP-TET-CIP-TOB-
CHL-SXT-NAL
blaTEM-1B;
blaCTX-M-15
sul2; gyrA; parC S83LþD87 N S8 þE84 V orf477 D
RP 48 ATM-CTX-CAZ AMP-TET-GEN-CIP-TOB-
CHL-SXT-NAL-STR
blaCTX-M-15 cmlA; gyrA; parC S83LþD87 N S8 þE84 V orf477; IS903 B2
RP 49 AMC-ATM-
CTX-CAZ
AMP-TET-GEN-CIP-TOB-
CHL-SXT-NAL-STR
blaTEM-1B;
blaCTX-M-15
aac(3)-II; tet(B); cmlA;
sul1; sul2; gyrA; parC
S83LþD87 N S8 þE84 V ISEcp1; orf477; IS903 B2
RP 50 AMC-CTX AMP-TET-GEN-CIP-TOB-
CHL-SXT-NAL-STR
blaCTX-M-15 aac(3)-II; tet(B); cmlA;
sul1; sul2; gyrA; parC
S83LþD87 N S8 þE84 V orf477; IS903 B2
RP 51 AMC-CTX AMP-TET-CIP-SXT-NAL-STR blaCTX-M-15 tet(B); gyrA; parC S83LþD87 N S8 þE84 V orf477; IS903; Int1 B2
RP 52 AMC-CTX AMP-TET-GEN-CIP-
SXT-NAL-STR
blaCTX-M-15 aac(3)-II; sul1;
gyrA; parC
S83LþD87 N S8 þE84 V B2
RP 53 AMC-ATM-
CTX-CAZ
AMP-CIP-SXT-NAL blaTEM-1B;
blaCTX-M-15
sul1; gyrA; parC S83LþD87 N S8 þE84 V orf477; IS903; Int1;
vint1 [dfrA17þdfrA29
þaadA5]
B2
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Letter to the Editor 403previously been reported as the most frequent on the gyrA
gene, in E. coli isolates of human origin.3 The parC gene
was detected in the isolates that were simultaneously
resistant to nalidixic acid and ciprofloxacin, and two non-
silent mutations were detected (S80I and E84V).
In conclusion, our study shows a wide variety of
resistance genes and inclusion of resistant genes in
integrons, in multiresistant ESBL-producing E. coli
isolates, obtained from urinary human samples, in
a clinical setting. It is important for clinicians and
infection-control practitioners to characterize the
different types of resistance quickly to allow efficient
reduction of the spread of these bacteria and help to
select more appropriate antibiotics.Acknowledgments
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